1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor-pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (Trial in progress)
    Meeting Abstract

    Hill, M.; Sharman, J. P.; Jurczak, W.; Coombs, C. C.; Wang, D.; Ku, N. C.; Guntur, A.; Shahda, S.; Leow, C. C.; Ghia, P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Coombs, C. C.; Pagel, J. M.; Shah, N. N.; Lamanna, N.; Munir, T.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, phase 3 IDHENTIFY trial
    Meeting Abstract

    DiNardo, C. D.; de Botton, S.; Risueño, A.; Schuh, A. C.; Lowenberg, B.; Kim, H. J.; Vyas, P.; Wei, A. H.; Stein, E. M.; Döhner, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • SELECT-AML-1 trial in progress: A phase 2 study of tamibarotene in combination with venetoclax and azacitidine in previously untreated adult patients selected for RARA-positive AML who are ineligible for standard induction therapy
    Meeting Abstract

    Kambhampati, S.; Eghtedar, A.; McMahon, C.; de Botton, S.; Pigneux, A.; Ball, B.; Borthakur, G.; Angela, V.; Gausman, J. A.; Baker, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • First results of a phase II study (STIMULUS-AML1) investigating sabatolimab plus azacitidine plus venetoclax in patients with newly diagnosed acute myeloid leukemia (ND AML)
    Meeting Abstract

    Zeidan, A. M.; Westermann, J.; Kovacsovics, T.; Assouline, S.; Schuh, A. C.; Kim, H. J.; Macias, G. R.; Sanford, D.; Luskin, M. R.; Stein, E. M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Trial in progress: Phase Ib/II study of siremadlin in combination with venetoclax plus azacitidine in patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy (IC)
    Meeting Abstract

    Daver, N. G.; Wei, A. H.; Stein, E. M.; DeAngelo, D. J.; Pathak, D.; Xu, Y. N.; Grzesiak, S.; Venditti, A.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Outcomes based on sequential use of venetoclax based therapy and targeted therapy in acute myeloid leukemia (AML)
    Meeting Abstract

    Stahl, M.; Shallis, R. M.; Derkach, A.; Goldberg, A. D.; Stein, A.; Stein, E. M.; Marcucci, G.; Zeidan, A. M.; Shimony, S.; DeAngelo, D. J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Safety and pharmacokinetics of calaspargase pegol in adults with newly diagnosed Philadelphia negative acute lymphoblastic leukemia: A phase 2/3 study
    Meeting Abstract

    Stock, W.; Park, J. H.; Emadi, A.; Abdul-Hay, M.; Cassaday, R. D.; Pullarkat, V.; Webster, J. A.; Pandya, S.; Mogul, M.; Shvenke, Y.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Plinabulin after autologous hematopoietic cell transplant to decrease duration of neutropenia and improve quality of life peri-transplant
    Meeting Abstract

    Shah, G.; Shulman, L.; Hanley, D.; Chung, D.; Datta, A.; Dhar, P.; Gupta, G.; Hassoun, H.; Hoover, E.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • A pilot plant based dietary intervention in MGUS and SMM is feasible and associated with reduction in insulin and leptin levels
    Meeting Abstract

    Shah, U.; Castro, F.; Anuraj, A.; Blaslov, J.; Adintori, P.; Derkach, A.; Pollak, M.; Maclachlan, K.; Mailankody, S.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save